One Moon Over Two Cities: Manila Embraces the "Chongqing Wave"
Image File
Original HTML

One Moon Over Two Cities: Manila Embraces the "Chongqing Wave"

News provided by

Western China International Communication Organization (WCICO)

Sep 15, 2026, 04:58 ET

MANILA, Philippines, Sept. 15, 2026 /PRNewswire/ -- "Chongqing Meets Manila – A Mid-Autumn Festival Celebration" opened at SM Mall of Asia on September 12, drawing around 400 guests from political, business, cultural, educational and tourism circles of both countries, along with overseas Chinese and students.

Hosted by the Chinese Embassy in the Philippines and the Information Office of the Chongqing Municipal People's Government and organized by the Western China International Communication Organization (WCICO), the two-day festival features a cultural performance, seven themed exhibitions and city and brand presentations, bringing Bayu culture, Mid-Autumn traditions, Chongqing cuisine and "Made in Chongqing" innovations to Manila.

Zhou Zhiyong, Chargé d'Affaires ad interim of the Chinese Embassy in the Philippines, said: "For a thousand years, the Maritime Silk Road has brought not only trade in goods, but also exchanges in culture, art, ideas and friendship between China and the Philippines. Today, through an event, a conversation, a dish and a smile, we come to know each other better and grow closer."

Maria Christina G. Aquino, Assistant Secretary of the Philippine Department of Tourism, noted that China is now the Philippines' fourth-largest tourist source market, with nearly 320,000 Chinese arrivals as of September 9. "I have already tasted some of them in advance, and they were all delicious," she said of the mooncakes on site.

Wu Changfan, Deputy Director-General of the Publicity Department of the CPC Chongqing Municipal Committee, said the festival turns the May online encounter into an in-person gathering, and that Chongqing looks forward to deeper cooperation with Manila in people-to-people exchanges, tourism promotion and trade, welcoming more Filipino friends to experience "Majestic Landscapes, Dynamic Chongqing."

The performances won warm applause, while booths on intangible heritage, "Study in Chongqing," traditional Chinese food and new energy vehicles drew steady crowds.

At the "China, An Opportunity: Chongqing Brands" promotion conference, Zhang Li of the CPC Chongqing Liangjiang New Area Committee highlighted new energy vehicles and HIFU technology already benefiting Philippine patients, as Happyyou International Travel signed a cooperation agreement with Philippine tourism organizations. Southwest University, Changan Automobile and Air China also presented study, industry and direct-flight opportunities.

A continuation of the May "Flying Across Mountains and Seas" twin-city campaign, the festival provides a face-to-face platform for Chongqing and the Philippines to explore cooperation in culture and tourism, education, automotive and beyond.

For more, please visit: https://www.ichongqing.info/

SOURCE Western China International Communication Organization (WCICO)

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302878776
Press Eligible
Yes
Press Eligible Reason
Business and trade promotion event highlighting tourism, education, automotive, healthcare technology, and cross-border cooperation.
Source Name
One Moon Over Two Cities
Original Summary

<p>MANILA, Philippines, Sept. 15, 2026 /PRNewswire/ -- "Chongqing Meets Manila – A Mid-Autumn Festival Celebration" opened at SM Mall of Asia on September 12, drawing around 400 guests from political, business, cultural, educational and tourism circles of both countries, along with overseas...</p>

Image URL
https://mmx.prnewswire.com/media/MS1988560/20260915042615EDT_image_1.jpg?id=OA2949225&p=facebook
Content Hash (SHA-256, erste 32 hex)
f3bac425714c87cd6559c50227961352
JIS Fall 2026 Returns to Miami Beach with Essential Holiday Sourcing, On Trend Talks and New Exhibitors
Image File
Original HTML

JIS Fall 2026 Returns to Miami Beach with Essential Holiday Sourcing, On Trend Talks and New Exhibitors

MIAMI, Sept. 15, 2026 /PRNewswire/ -- JIS Fall 2026 returns to the Miami Beach Convention Center, October 16-19, 2026, as an essential sourcing destination for jewelry retailers making critical final inventory decisions ahead of the holiday selling season. With access to more than 600 exhibitors, immediate at-show delivery and future-order buying, retailers can fill inventory gaps, replenish proven sellers and secure trend-driven merchandise before peak demand.

Strategically timed ahead of the busiest retail period of the year, JIS Fall brings independent retailers, multi-store operators and buying groups together with suppliers from leading jewelry-producing regions around the world. Buyers can efficiently restock fast-moving merchandise, respond to late-breaking consumer trends and refresh their holiday assortments across fine jewelry, fashion jewelry, bridal, gemstones, silver, gold, accessories, technology and business services.

Holiday sourcing remains at the center of the JIS Fall experience. Complementing the buying floor, this year's show will offer timely education, networking events and interactive activations designed to help attendees identify what's selling, meet new suppliers and make informed purchasing decisions throughout the four-day event.

On Trend Talks will bring current industry conversations directly to the show floor through 30-minute sessions in the Trends Lounge. On Friday, October 16 at 1:00 p.m., Jen Cullen Williams will moderate "Beyond Metal: What's New in Alternative Materials" with Victoria Gomelsky of JCK Magazine.

On Saturday, October 17 at 1:00 p.m., Williams and Gomelsky will return for "What's Trending in Design," exploring the ideas and influences shaping jewelry design. The series will also feature a session Sunday, October 18 at 1:30 p.m. with "Ready for the Rush: Holiday Retail Trends Straight Off the JIS Floor," featuring Williams and consultant Tammy Lail in a discussion about product and design trends and how retailers are preparing for the holiday season.

"For jewelry retailers, timing is everything, and JIS Fall provides an important opportunity to make critical final adjustments to holiday assortments," said Sara McDonough, Event Director of JIS. "The ability to source from more than 600 exhibitors, take immediate delivery of inventory and place future orders makes the event especially valuable this close to peak selling season. This year's talks, activations and networking experiences will give buyers even more ways to discover what's new and make every day in Miami Beach productive."

The show's networking schedule will begin with Seasonal Kickoff: JIS Welcome Reception on Friday, October 16 from 6:00 to 8:00 p.m. in the JIS Lobby. The reception will spotlight new JIS exhibitors and give attendees and exhibitors a relaxed setting to connect after the first day of buying. JIS Unwrapped will continue the experience on Saturday, October 17 from 6:00 to 7:30 p.m. in the show floor Food Court.

Throughout the event, rotating refreshment pop-ups will appear in the Brands, Accessories and Gifts, Equipment, Technology and Services, and Lab Grown pavilions. Daily Galleria beverage breaks will also offer attendees a convenient afternoon pause in the Galleria Lounge.

Additional planned activations include a custom embroidery experience, a puppy activation, an interactive gem color forecast, and a gift-wrapping studio, creating more opportunities for attendees to pause, participate and enjoy the show beyond the buying floor.

JIS Fall will also welcome a range of new exhibitors, giving retailers additional opportunities to discover fresh collections and establish supplier relationships ahead of the holidays. Among the new names currently featured are Jewels by Anu, Previato Corp, Sky Wing, Orchid Gems, Om Color Diamonds, Athra, AAB Style, Augusta Estrada Jewelry, Estojos Baldi, Gurjar Global and Jewelerette & Co. Additional first-time participants can be found in the official JIS Fall exhibitor directory.

Designed exclusively for qualified members of the jewelry trade, JIS Fall gives retailers a critical opportunity to react before the holidays: replenishing best sellers, replacing fast-moving stock, testing trend-driven additions and expanding assortments while there is still time to influence fourth-quarter sales. With immediate and future-order purchasing available in one marketplace, buyers can address urgent inventory needs while planning what comes next.

Registration for JIS Fall 2026 is currently open. Qualified jewelry industry professionals are encouraged to register before October 1 and begin planning appointments to maximize their time at the show.

Beginning October 1, a $25 non-refundable registration fee (inclusive of applicable taxes) will apply to registrations for retailers, wholesalers, designers, distributors, diamond and gemstone dealers, and attending professionals.

To register or learn more, visit www.jisshow.com/fall.

About Jewelers International Showcase (JIS)

In 1979, Jewelers International Showcase (JIS) launched its first trade-only jewelry show. Nearly five decades later, the JIS brand continues to bring together an array of leading worldwide manufacturers and wholesalers ready to market and sell their products and services to thousands of trade-only jewelry attendees from Latin America, the Caribbean, the United States and beyond. JIS Shows are the premier events for immediate at-show delivery. Each event is strategically produced around the seasonal buying needs of retailers and their customers.

All JIS shows are produced by RX USA, the world's leading event organizer, with more than 350 events in 25 countries. For additional information on all JIS Events, visit jisshow.com.

About RX

RX is a global leader in events and exhibitions, leveraging industry expertise, data and technology to build businesses for individuals, communities and organizations. With a presence in 25 countries across 42 industry sectors, RX hosts approximately 350 events annually. RX is committed to creating an inclusive work environment for all our people. RX empowers businesses to thrive by leveraging data-driven insights and digital solutions. RX is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.rxglobal.com.

SOURCE Jewelers International Showcase (JIS)

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302878158
Press Eligible
Yes
Press Eligible Reason
Trade-industry event announcement providing sourcing, exhibitor, and networking information for jewelry retailers and professionals.
Source Name
Unknown Company
Original Summary

<p>MIAMI, Sept. 15, 2026 /PRNewswire/ -- JIS Fall 2026 returns to the Miami Beach Convention Center, October 16-19, 2026, as an essential sourcing destination for jewelry retailers making critical final inventory decisions ahead of the holiday selling season. With access to more than 600...</p>

Image URL
https://mmx.prnewswire.com/media/MS1987831/Jewelers-International-Showcase.jpg?id=OA2947370&p=facebook
Content Hash (SHA-256, erste 32 hex)
de70efc6d7998319c3a4dcd6ee8ccb1c
Nemak, S.A.B. de C.V. Announces a Tender Offer and Consent Solicitation for Any and All of Its Outstanding 2.250% Senior Notes Due 2028
Original HTML

Nemak, S.A.B. de C.V. Announces a Tender Offer and Consent Solicitation for Any and All of Its Outstanding 2.250% Senior Notes Due 2028

MONTERREY, Mexico, Sept. 15, 2026 /PRNewswire/ -- NEMAK, S.A.B. de C.V. (the "Company") announced today that it has commenced an offer to purchase (the "Tender Offer") any and all of its outstanding 2.250% Senior Notes due 2028 (Regulation S Notes: ISIN XS2362994068 / Common Code 236299406; Rule 144A Notes: ISIN XS2362996519 / Common Code 236299651) (the "Notes") and a solicitation of consents (the "Consents") to amend the indenture relating to the Notes (the "Consent Solicitation" and, together with the Tender Offer, the "Offer"), upon the terms and subject to the conditions set forth in the Offer Document (as defined below).

The Tender Offer

The Tender Offer will expire at 11:00 a.m., New York time (5:00 p.m., Central European Time), on September 22, 2026 (such time and date, as the same may be extended, the "Expiration Date"). Noteholders who validly tender their Notes and deliver their corresponding Consents at or prior to the Expiration Date and do not validly withdraw their Notes and revoke their corresponding Consents prior to the Withdrawal Deadline (as defined below), and whose tender of Notes and delivery of Consents are accepted by the Company, will receive an amount equal to €1,000 for each €1,000 principal amount of Notes tendered (the "Total Consideration"), in addition to accrued and unpaid interest up to (but excluding) the Settlement Date, as defined below ("Accrued Interest") and additional amounts thereon.

The terms and conditions of the Offer are set forth in an offer to purchase and consent solicitation statement dated the date hereof (as it may be amended or supplemented from time to time, the "Offer Document"). Subject to applicable law, the Company, in its sole discretion, may amend, extend, terminate or withdraw the Offer.

The purpose of the Tender Offer is to acquire all of the outstanding Notes. Notes validly tendered (and not validly withdrawn) and accepted for purchase by the Company in the Tender Offer will be retired and cancelled. On or after the Settlement Date, the Company intends but is not obliged to issue a notice of redemption with respect to all Notes that may remain outstanding following the Settlement Date, in accordance with the terms of the indenture governing the Notes (the "Indenture").

Conditions to the Offer

The Company's obligation to accept for purchase and to pay for Notes validly tendered and not withdrawn pursuant to the Tender Offer is subject to the satisfaction or waiver of certain conditions, which are more fully described in the Offer Document, including, among others, the valid receipt of the Required Consents (as defined below).

The Consent Solicitation

The Consent Solicitation is being made concurrently with the Tender Offer. Under the Consent Solicitation, the Company is soliciting Consents to certain proposed amendments to the Indenture, to eliminate substantially all of the restrictive covenants, certain events of default and certain additional covenants and rights contained in the Notes and the Indenture and to shorten (i) the minimum notice period to noteholders required for a redemption from 30 days to three (3) Business Days prior to the redemption date; and (ii) the minimum period to provide an officers' certificate to the Trustee in connection with the redemption from 45 days to three (3) Business Days prior to the redemption date (the "Proposed Amendments").

Noteholders who desire to tender their Notes must deliver Consents to the Proposed Amendments. Noteholders may not deliver Consents without tendering the related Notes and may not tender their Notes without delivering their Consents.

Adoption of the Proposed Amendments is conditioned, among other things, on the valid delivery to the Tender Agent appointed by the Company (named below) of the Consents of noteholders representing at least a majority of the aggregate principal amount of the outstanding Notes (the "Required Consents"). The Proposed Amendments will be implemented through the execution of a supplemental indenture to the Indenture (the "Supplemental Indenture"), which will be executed by the Company and the Trustee on or promptly following the Expiration Date, if the Required Consents are received. The Supplemental Indenture will be effective from the date on which the Supplemental Indenture is executed, provided that such Proposed Amendments shall only become operative on the Settlement Date, once the Required Consents are received, upon deposit of the Total Consideration, in immediately available funds, with Euroclear Bank SA/NV or Clearstream Banking, société anonyme, as applicable, in respect of such tendered Notes.

Withdrawal Rights

Notes tendered may only be withdrawn and revoked prior to 11:00 a.m., New York time (5:00 p.m. Central European Time) on September 22, 2026, unless extended by us (the "Withdrawal Deadline"). No Noteholder may withdraw its tender of Notes without revoking the corresponding Consents or revoke its Consents without withdrawing the corresponding tender of Notes. If the Offer is extended, the Withdrawal Deadline will be extended to the earlier of (i) the Expiration Date (as extended) and (ii) the tenth (10th) Business Day after the commencement date of the Offer. The Notes may also be validly withdrawn in the event that the Offer has not been consummated within sixty (60) Business Days after the commencement date of the Offer.

Settlement

Subject to the terms and conditions of the Offer being satisfied or waived and to the Company's right to amend, extend, terminate or withdraw the Offer, the Company expects that payment for all Notes validly tendered at or prior to the Expiration Date and accepted by the Company will be made on the date the Company selects promptly following the Expiration Date (the "Settlement Date").

The Company expects the Settlement Date (subject to any extension of the Expiration Date) to be September 24, 2026.

Scotia Capital (USA) Inc. is the dealer manager and solicitation agent (the "Dealer Manager") for the Offer. D.F. King Ltd has been appointed as the tender, tabulation and information agent (the "Tender Agent") for the Offer.

Any questions or requests for assistance in connection with the Offer, may be directed to the Dealer Manager:

Scotia Capital (USA) Inc.

250 Vesey Street

New York, New York 10281

United States of America

Attention: Liability Management Group

Collect: +1 (212) 225-5559

Toll-free: +1 (800) 372-3930

Email: [email protected] 

The delivery of electronic instructions or requests for additional copies of the Offer Document or related documents, which may be obtained free of charge, may be directed to the Tender Agent:

D.F. King Ltd.

51 Lime Street, London

EC3M 7DQ, United Kingdom

Banks and brokers call:

+44 20 7920 9700

Offer Website: https://clients.dfkingltd.com/nemak/

Email: [email protected]

Noteholders may also contact their broker, dealer, bank, custodian, trust company or other nominee or intermediary through which they hold Notes for assistance concerning the Offer.

The Offer Document will be distributed to noteholders promptly. Copies of the Offer Document are available for noteholders at the following Offer website: https://clients.dfkingltd.com/nemak/.

This press release is not an offer to sell or a solicitation of an offer to buy any security. The Offer is being made solely pursuant to the Offer Document.

The Offer does not constitute, and may not be used in connection with, an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not permitted by law or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such offer or solicitation.

In any jurisdiction in which the Offer is required to be made by a licensed broker or dealer and in which the Dealer Manager, or any affiliates thereof, are so licensed, the Offer will be deemed to have been made by the Dealer Manager or such affiliates, on behalf of the Company.

Forward-Looking Statements

This release may contain certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to risks, uncertainty and changes in circumstances, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. All statements contained herein that are not clearly historical in nature are forward-looking and the words "anticipate", "believe", "expect", "estimate", "plan" and similar expressions are generally intended to identify forward-looking statements. The Company is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise. More detailed information about these and other factors is set forth in the Offer Document.

About the Company

Nemak, S.A.B. de C.V. is a publicly traded variable capital stock corporation (sociedad anónima bursátil de capital variable) incorporated on December 6, 1993, in San Pedro Garza García, Nuevo León, Mexico. Since its incorporation, it has operated under the corporate names Acciones Corporativas de México, S.A. de C.V., Tenedora Nemak, S.A. de C.V., and Nemak, S.A. de C.V., adopting its current corporate name, Nemak, S.A.B. de C.V., in 2015 in connection with its listing on the Mexican Stock Exchange (Bolsa Mexicana de Valores). Although Nemak, S.A.B. de C.V. was incorporated in 1993, its operations date back to 1981 and, through its subsidiary Nemak México, S.A.

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302878733
Press Eligible
Yes
Press Eligible Reason
Corporate debt tender offer and consent solicitation by Nemak, relevant to investors and finance professionals.
Source Name
Unknown Company
Original Summary

<p>MONTERREY, Mexico, Sept. 15, 2026 /PRNewswire/ -- NEMAK, S.A.B. de C.V. (the "Company") announced today that it has commenced an offer to purchase (the "Tender Offer") any and all of its outstanding 2.250% Senior Notes due 2028 (Regulation S Notes: ISIN XS2362994068 / Common Code...</p>

Content Hash (SHA-256, erste 32 hex)
a7b90b1c7ef70af128b55e69d0771ed8
Ontinue Reports 2025 Greenhouse Gas Emissions Results, Advancing SBTi-Validated Climate Commitments
Image File
Original HTML

ZURICH, Switzerland, Sept. 15, 2026 /PRNewswire/ -- Ontinue, a leading MXDR partner providing nonstop managed security operations through its Agentic SOC, today published the results of its greenhouse gas (GHG) emissions inventory. The report shows continued progress toward the company's SBTi-validated near-term and net-zero targets, including a 2.5% year-over-year reduction in Scope 2 emissions tied to the optimization of Ontinue's global office footprint.

Total emissions across Scopes rose by approximately 3% compared to 2024. Ontinue attributes the increase to two factors: continued business growth that increased employee business travel, and a planned methodology upgrade that moved fuel and energy-related activity accounting from a spend-based to an activity-based approach. The latter change improves the precision of Ontinue's emissions data and reflects the kind of reporting maturity SBTi expects companies to build over time.

"We're growing as a business and we're measuring that growth more precisely than we used to," said Moritz Mann, Chief Executive Officer of Ontinue. We're pleased to see that we're still making real headway on the parts of our footprint we control directly."

2025 Emissions Breakdown

As in prior years, Scope 3 continues to represent the substantial majority of Ontinue's footprint, reflecting the company's office-based, software-led business model. Scope 1 emissions remained at zero, and Scope 2 emissions totaled 12.59 tCO₂e on a location-based basis, down from the prior year as Ontinue continued to streamline its office locations.

Continued Alignment with Science-Based Targets

Ontinue's near-term targets for Scopes 1 and 2, and its long-term net-zero target across Scopes 1, 2, and 3, remain validated by the Science Based Targets initiative (SBTi), the global authority that enables companies to set emissions reduction targets in line with climate science and the Paris Agreement's goal of limiting warming to 1.5°C.

Ontinue's sustainability strategy continues to focus on decarbonizing its own operations, working with suppliers and partners on shared reductions, and reporting progress transparently. Looking ahead, the company plans to extend the activity-based measurement approach it applied to fuel and energy-related activities in 2025 to its purchased goods and services category, its largest source of emissions, beginning with its highest-spend suppliers.

To learn more about Ontinue, please visit www.ontinue.com.

About Ontinue

As a leading provider of AI-powered managed security operations, Ontinue is on a mission to give every organization the freedom to focus on what they do best; by making nonstop security excellence accessible, not just aspirational. By combining advanced AI with deep human expertise, Ontinue delivers managed security operations that are tailored to each organization's unique environment, operational needs, and risk profile.

Ontinue's ION SecOps Platform integrates AI-driven insights, automation, and real-time collaboration to continuously prevent, detect, and respond to threats. With deep expertise in Microsoft security technologies, Ontinue helps customers maximize the value of their existing investments while achieving stronger, more scalable security outcomes.

Continuous protection. AI-powered Nonstop SecOps. That's Ontinue.

Media Contact

Alison Raymond

[email protected]

SOURCE Ontinue

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302877709
Press Eligible
Yes
Press Eligible Reason
Corporate sustainability reporting from a managed cybersecurity company, including emissions results and climate targets.
Source Name
Unknown Company
Original Summary

<p>ZURICH, Switzerland, Sept. 15, 2026 /PRNewswire/ -- Ontinue, a leading MXDR partner providing nonstop managed security operations through its Agentic SOC, today published the results of its greenhouse gas (GHG) emissions inventory. The report shows continued progress toward the company's...</p>

Image URL
https://mmx.prnewswire.com/media/MS633967/ONTINUE-Logo.jpg?id=OA2946205&p=facebook
Content Hash (SHA-256, erste 32 hex)
5b82e0da6ade83824cce2eab0ce29327
RIGHT CARE, RIGHT PLACE: NUHS MARKS A DECADE OF ADVANCING VALUE-BASED CARE, SAVING 18,225 BED DAYS
Image File
Original HTML

The NUHS Appropriate and Value-Based Care Symposium 2026 showcases a decade of proven impact — providing value-based care to over 300,000 patients, saving 18,225 bed days, and advancing a model for healthcare transformation across Singapore

SINGAPORE, Sept. 15, 2026 /PRNewswire/ -- More than 300,000 patients at the National University Health System (NUHS) have benefited from a decade-long transformation in how healthcare is measured and delivered, reducing hospital bed days by 18,225, while generating over SG$13 million in annual cost avoidance. The results prove that better patient outcomes and smarter healthcare spending are not mutually exclusive.

Today, NUHS commemorated this milestone by bringing together healthcare leaders, clinicians and policymakers at the NUHS Appropriate and Value-Based Care (AVBC) Symposium 2026 to showcase a model that has influenced national healthcare policy and demonstrated what is possible when care is measured by outcomes that matter to patients.

Since becoming the first healthcare cluster in Singapore to adopt the Value-Driven Outcomes (VDO) framework in 2015, NUHS has prevented 793 emergency readmissions within a 30-day period and improved outcomes across more than 75 clinical conditions and programmes spanning primary, secondary and tertiary care.

Officiated by Guest of Honour Mdm Rahayu Mahzam, Minister of State, Ministry of Digital Development and Information & Ministry of Health (MOH), the symposium marks a milestone in Singapore's healthcare transformation — from the first Value-Driven Outcomes (VDO) pilots at the National University Hospital (NUH), to scaling uptake across the cluster, and shaping national adoption.

To celebrate a decade of value-based healthcare and consolidate key lessons gained, NUHS will also be launching two books, A Practical Framework for Measuring Health Outcomes at the National University Health System, Singapore: The First Decade of Our Journey, and NUHS Clinical Outcomes Book, at the symposium. The NUHS Clinical Outcomes Book is the first of its kind in Singapore.

The two publications capture the collective efforts of countless healthcare professionals, researchers and partners, documenting the lessons learnt, innovations pioneered and impact achieved along the journey.

"Healthcare systems around the world are continually being challenged to deliver better outcomes, greater value, and deeper trust simultaneously," said Adj A/Prof Diarmuid Murphy, Group Chief Value Officer, NUHS. "A decade in, the data speaks for itself: when you measure what matters to patients, the system works better for everyone. The question now isn't whether value-based care works. It's how fast we can scale it."

A decade of measurable impact

Beginning with 14 pilot conditions at the National University Hospital (NUH) in 2015, the VDO methodology demonstrated significant improvements in outcomes and costs within two years, providing a strong foundation for wider implementation.

This led to the national adoption of the methodology through MOH's National Value-Driven Care (VDC) programme in 2017, which enabled public acute hospitals to benchmark outcomes and costs, share best practices, and drive continuous improvements in care and value.

Over the past decade, what started with a small number of pilot conditions has since evolved into a system-wide VDO initiative, expanding progressively from 18 conditions in 2017 to now more than 75 clinical conditions, service lines and population health programmes extending across primary, secondary and tertiary care.

The impact has also extended beyond individual projects to drive system-wide transformation. Healthcare workshops and training programmes have been conducted cluster wide, equipping healthcare professionals with the knowledge and skills to embed value into everyday care delivery.

Measuring what matters to patients

With the evolution of NUHS's value-based healthcare journey, the focus has expanded beyond traditional clinical indicators to include a more holistic understanding of patient wellbeing.

In stroke care at NUH, Patient-Reported Outcome Measures (PROMs) are being used to capture non-motor symptoms and aspects of wellbeing for young adult stroke survivors aged 18-60 years old, which may not surface in a standard consultation. While AVBC is currently enabled by measuring care processes such as functional recovery, length of stay and readmissions, they may not fully highlight concerns such as anxiety symptoms, depressive symptoms, fatigue, sleep disturbance, despite representing a significant burden for stroke survivors.

NUHS's stroke PROMs data found that anxiety symptoms (39.4 per cent), pain interference (31.5 per cent), depressive symptoms (26.8 per cent), fatigue (24.4 per cent) and sleep disturbance (16.5 per cent) were among the challenges most commonly reported by patients recovering from stroke.

These findings highlight the importance of looking beyond clinical recovery alone. By combining patient-reported outcomes with clinical outcomes data, a key principle of value-based healthcare, NUHS gains a more holistic understanding of recovery, enabling more personalised care and identifying opportunities to improve care delivery.

Delivering care in the right place: From hospital wards to patients' homes

At the heart of NUH's transformation is a fundamental redesign of where and how care is delivered. That same principle underpins NUHS@Home, NUHS's Mobile Inpatient Care at Home programme, which brings hospital-level care safely into patients' homes. Since its launch in 2020, the programme has transformed care for more than 11,400 patients and saved over 68,200 hospital bed days, helping to shift care from a traditional hospital-first model to a home-first model where clinically appropriate.

Under its VDO framework, NUHS@Home tracks measures including clinical outcomes, patient safety and patient experience. Among patients cared for between May 2022 and June 2026, 87 per cent completed their care at home without requiring a return to hospital, while the programme's 30-day readmission rate was 9.3 per cent. More than 95 per cent of patients would also recommend the service to others. Together, these results demonstrate that hospital-level inpatient care can be delivered at home safely, effectively and at scale. This shift forms a key pillar of NUHS's wider "Home First" strategy, which aims to anchor care in the community, and deliver it in the right place and at the right time.

NUHS is exploring expanding beyond hospital-at-home care into a connected ecosystem of virtual and community-based services. Central to this is the Virtual Care Centre (VCC), a digital front door for the triage and assessment of urgent medical concerns. Patients can receive prompt virtual assessment and be directed to the most appropriate care pathway, enabling Emergency Departments to focus on those who truly require urgent acute care.

Initially established by Alexandra Hospital as a post-discharge helpline, NUHS is also reviewing evolving VCC into part of the broader ecosystem of delivering care in the community, alongside virtual professional consults and chronic disease management services. Since 2020, the service has handled more than 6,000 medical calls, with 60 per cent of callers advised to continue monitoring their condition and only 13.5 per cent requiring referral to 995 or the Emergency Department. This demonstrates how virtual care can improve access to the right care while helping to preserve physical hospital capacity.

Proven impact across clinical conditions

One of the earliest pilot projects at the genesis of NUHS's VDO adoption was Total Knee Replacement (TKR) care at NUH, which demonstrated how measuring outcomes across the full care journey could lead to meaningful improvements.

From 2017 to 2021, perioperative blood transfusion rates fell from 12.52 per cent to 3.58 per cent, while venous thromboembolism prophylaxis rates improved from 90.05 per cent to 95.02 per cent, reducing the risk of post-surgery blood clots. Length of stay has also reduced from around four to five days to approximately one to two days today, enabling patients to return more quickly to daily life — without compromising safety or outcomes.

The same commitment to improving patient outcomes for TKR care was mirrored in the Enhanced Recovery After Surgery (ERAS) evidence-based interventions pioneered by clinicians at Ng Teng Fong General Hospital (NTFGH).

Beyond focusing on the surgery itself, multidisciplinary teams examined what helped patients recover better, from preparation before the operation to rehabilitation after. This included pre-operative measures such as identifying and optimising patients with low haemoglobin, improving nutrition, preparing patients through prehabilitation, and supporting them with more effective pain control and early mobilisation after surgery.

ERAS enabled patients to return home within one to two days, compared with four to five days previously.

The VDO approach has been applied across dozens of other conditions, from cardiac procedures to cancer care, consistently demonstrating that when we measure what matters, care improves. (See Annex for a case study on same-day discharge for percutaneous coronary intervention)

Looking to the next decade and beyond

As NUHS embarks on its next decade, the principles of appropriate and value-based care will be woven even more deeply into standard practice — informing workforce training, care pathway redesign, innovation adoption, and outcome measurement.

By continually measuring what matters and improving care delivery, NUHS is building a healthcare system that better serves patients and caregivers today, and in the years ahead, anchored on a simple but powerful goal: delivering care that is appropriate, sustainable, and meaningful to patients' lives.

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302878781
Press Eligible
Yes
Press Eligible Reason
Healthcare system announces measurable value-based care outcomes, operational efficiencies, and digital care innovations for industry professionals.
Source Name
RIGHT CARE, RIGHT PLACE
Original Summary

<p>The NUHS Appropriate and Value-Based Care Symposium 2026 showcases a decade of proven impact — providing value-based care to over 300,000 patients, saving 18,225 bed days, and advancing a model for healthcare transformation across Singapore SINGAPORE, Sept. 15, 2026 /PRNewswire/ -- More...</p>

Image URL
https://mmx.prnewswire.com/media/MS1988483/20260915014733EDT_image_1.jpg?id=OA2948991&p=facebook
Content Hash (SHA-256, erste 32 hex)
94025f32de9158fe94c6ab7e442261ff
Naviq recognised by HFS Research as an Enterprise Innovator in travel transformation
Image File
Original HTML

Independent industry recognition highlights Naviq's specialist travel expertise, proprietary technology and AI-first approach to enterprise transformation

LONDON, Sept. 15, 2026 /PRNewswire/ -- Launched in July 2026 Naviq, the vertical AI company purpose-built for the global travel industry, has been recognised as a Horizon 2: Enterprise Innovator by HFS Research.

The recognition reflects Naviq's travel expertise and AI-first technology, helping organisations tackle complex technology challenges and deliver measurable outcomes.

IBS Group formed Naviq with a $500 million investment and 2,000 employees, serving the travel sector across aviation, hospitality, cruise and airport operations worldwide.

HFS Research highlighted Naviq's specialist industry focus and software heritage as key differentiators, recognising its ability to deliver tailored AI-first transformation for travel businesses.

"IBS Group is moving travel from AI experimentation to AI execution. Naviq's launch as an independent AI-first company builds on that vision, pairing specialised domain expertise with proven technical delivery. Together with decades of operational travel IP, this forms a differentiator that few providers can match," said Melissa Fersht, Executive Research Leader, HFS Research.

Naviq's approach is already delivering measurable outcomes for travel organisations. For a European airline, Naviq streamlined more than 45 applications, achieving 60% cost savings while helping unify flight operations through modernisation and cloud migration. For a leading airline in APAC, Naviq built an AWS-based Partner Integration Hub that enabled the onboarding of more than 500 partners, alongside the decommissioning of legacy systems within nine months.

"Naviq is helping move travel from AI experimentation to AI-first execution. By combining deep travel expertise with proven technology and transformation capabilities, we are helping customers address complex challenges and deliver measurable outcomes," said Moizzur Rahman, President, Naviq.

About Naviq Technology

Naviq is an AI-first vertical technology transformation company purpose-built for the travel industry. We help travel enterprises modernise platforms, simplify complex systems, and create seamless digital experiences that make every journey more joyful.

Our mission is to co‑pilot a digital future for travel by building smart, intuitive systems that help our customers grow and unlock new opportunities.

From airlines, airports, cruise lines, vacation providers, and hospitality groups, we combine deep travel domain expertise with strong engineering capabilities, turning disconnected systems into unified launch pads for accelerated growth. Our teams work side by side with customer teams to strengthen operations, improve performance, and deliver measurable outcomes at every touchpoint, so organisations can move faster with confidence and clarity.

Further information can be found at https://naviqplc.com. Follow us: LinkedIn

SOURCE Naviq Technology

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302876421
Press Eligible
Yes
Press Eligible Reason
Company recognition and AI-driven technology transformation services for enterprise travel organizations.
Source Name
Unknown Company
Original Summary

<p>Independent industry recognition highlights Naviq's specialist travel expertise, proprietary technology and AI-first approach to enterprise transformation LONDON, Sept. 15, 2026 /PRNewswire/ -- Launched in July 2026 Naviq, the vertical AI company purpose-built for the global travel...</p>

Image URL
https://mmx.prnewswire.com/media/MS1986446/HFS-announcement.jpg?id=OA2943170&p=facebook
Content Hash (SHA-256, erste 32 hex)
d182b699a14f0544784dda4d424edd1f
Momax Wins 2026 IFA Innovation Award in Berlin
Image File
Original HTML

Momax Wins 2026 IFA Innovation Award in Berlin

1-Power S.Pass² Air Sets a New Benchmark for Semi-Solid-State Battery Portable Power and Premium Craftsmanship

HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Momax, the global leader in cutting-edge Semi-Solid-State Battery (SSB) technology for mobile power banks and a design-led pioneer in smart charging solutions, has been awarded the prestigious 2026 IFA Innovation Award (Best in Mobility) for its breakthrough 1-Power S.Pass² Air Magnetic Wireless Power Bank. The win highlights Momax's engineering prowess and sets a new benchmark for safe, ultra-compact everyday charging.

This marks the second consecutive year Momax has earned top honors at IFA Berlin. The 1-Power S.Pass² Air is the world's thinnest stainless steel mirror-finish power bank at just 6.0 mm thick, snapping seamlessly onto magnetic-compatible devices or sliding effortlessly into a pocket or clutch. It pairs certified Qi2 high-speed wireless charging with refined, architectural minimalism. Alongside the flagship launch, Momax has introduced its signature Dusky Cherry capsule collection — a bold, design-forward color palette for modern travelers and tech enthusiasts.

Momax's design and technology leadership is widely recognized globally. In addition to back-to-back IFA Innovation Awards, recent flagship wins include the iF Design Award 2026, Golden Pin Design Award 2025, TechRadar Picks 2026 and CES Picks 2026. These honors affirm Momax's founding vision: real-world convenience paired with durable materials, high-density cell chemistry and contemporary industrial design.

To further advance safety in high-density power banks, Momax has launched its SS Assurance Mark framework. Built on three rigorous pillars — certified semi-solid-state cells, proprietary thermal and mechanical puncture stress-testing, and compliance with international safety standards including GB 38031:2025, UN38.3, CCC and RoHS — the framework guarantees sustained high-output performance under demanding travel conditions. Upcoming Momax power banks will also integrate with the Recharge Hub companion app, giving users real-time visibility into battery health, wattage output and operating temperatures from their smartphones.

About Momax

Founded in Hong Kong in 2003, Momax is a design-driven consumer electronics brand and a leading force in fashion tech and creator tech, specializing in smart charging, portable energy storage, mobile accessories and IoT smart living solutions. A multi-year recipient of the Red Dot Design Award, iF Design Award, IFA Innovation Awards and the Hong Kong Designers Association "Best Brand Award," Momax treats technology as an applied art form. Guided by its core ethos — Recharge for Life — Momax delivers safe, high-performance, beautifully crafted products to users across 50+ countries and regions worldwide.

Media Contact:

Momax PR & Corporate Communications Team

Email: [email protected]

Website: https://www.momax.net/

SOURCE MOMAX SMART INTERNATIONAL LIMITED

Share this article

Class (B2B/B2C)
B2C
Ingest Status
Rewritten
Dedupe hash
prn_302878615
Press Eligible
Yes
Press Eligible Reason
Company news about a consumer electronics product, technology innovation, and industry award.
Source Name
Unknown Company
Original Summary

<p>1-Power S.Pass² Air Sets a New Benchmark for Semi-Solid-State Battery Portable Power and Premium Craftsmanship HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Momax, the global leader in cutting-edge Semi-Solid-State Battery (SSB) technology for mobile power banks and a design-led pioneer in...</p>

Image URL
https://mmx.prnewswire.com/media/MS1988388/20260914221416EDT_image_2.jpg?id=OA2948692&p=facebook
Content Hash (SHA-256, erste 32 hex)
73363bd519ef0f36f2efb7440dcafc63
MGI Tech Launches VisiOmics in Europe and Unveils AI-Enabled Pathology Portfolio at ECP 2026
Image File
Original HTML

MGI Tech Launches VisiOmics in Europe and Unveils AI-Enabled Pathology Portfolio at ECP 2026

From Tissue to Answer: Integrated Solutions for Tissue and Molecular Pathology, from multiplex immunofluorescence to sample-to-result sequencing, powered by AI

STOCKHOLM, Sept. 15, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life science, today announced the European launch of VisiOmics (PMIF-20RS)*, a fully automated multiplex immunofluorescence (mIF) staining and imaging system, at the 38th European Congress of Pathology (ECP 2026), held in Stockholm from 12 to 16 September 2026.

Under the theme "From Tissue to Answer", the launch anchors a comprehensive pathology portfolio spanning tissue and molecular pathology. Whether the question is asked of proteins in a tissue section or of nucleic acids in a sample, MGI's platforms deliver an accurate answer with AI embedded at every step.

VisiOmics: is now commercially available in Europe

VisiOmics is a fully automated mIF staining and imaging system that brings high-plex, automated tissue analysis within reach of routine laboratory workflows. VisiOmics enables multiplex detection of protein markers within a single tissue section, allowing researchers to characterize cell populations and investigate their spatial organization within the tissue microenvironment:

- More than 20-plex detection per run, expandable to more than 100 markers from a single tissue section via cyclic staining

- Walk-away automation of the full staining-to-imaging workflow

- AI-powered image analysis with FluoXpert Vision — including cell segmentation, phenotyping and spatial analysis — supported by a dedicated AI assistant that lowers the barrier for downstream analysis and data visualization.

"To gain deeper insights into disease biology, pathology research is increasingly combining morphological assessment with multiplex spatial proteomics," said Fang Chen, Vice President of MGI and General Manager of Europe & Africa at MGI. "With VisiOmics now available in Europe, alongside PrepALL and AIO for molecular pathology, we are offering a complete 'From Tissue to Answer' portfolio, whether the starting point is proteins in tissue or nucleic acids in a sample."

MGI is also partnering with the Fraunhofer Institute for Integrated Circuits IIS to demonstrate the compatibility of multiplex immunofluorescence images generated by VisiOmics with MIKAIA®, Fraunhofer IIS's image analysis software for digital pathology and spatial biology research. The collaboration aims to show how researchers can use VisiOmics image data within MIKAIA workflows for cell segmentation, phenotyping and spatial analysis. This work supports greater flexibility in downstream analysis, helping laboratories connect automated tissue imaging with tools suited to their research questions.

Also on display: Customisable High-Throughput Multiplex Tissue Imaging

AI-based pathology research depends on well-characterised tissue image datasets. To support their generation at scale, MGI is also presenting Path-P96 WF, a customisable platform for automated multiplex immunofluorescence staining and imaging using standard pathology slides. The system processes up to 32 slides per batch, supports continuous loading and walk-away operation, and enables detection of more than 100 protein markers through cyclic staining.

Designed to accommodate different research workflows, Path-P96 WF can be configured for applications in drug discovery and spatial biology, including target validation, spatial phenotyping and image dataset generation for AI-based pathology research.

Molecular pathology: From Library Prep to Integrated Reporting

MGI now offers PrepLPS(PrepALL Library Prep Edition), a compact liquid-handling platform for NGS library preparation with eight independent channels (0.5–1,200 µL), AI-based machine vision and ready-to-run workflows. Early Access is now open for European laboratories.

AIO (All-in-one) condenses the entire workflow — library preparation, sequencing and reporting — into a single sample-to-result platform: nucleic acid in, report out, in about 11 hours with roughly 10 minutes of hands-on time. AIO is demonstrated live at the booth, and the platform is open for OEM partnerships in Europe.

AI Across the Portfolio: From Analysis to Intelligent Lab Agents

Across the portfolio, AI is built in, not bolted on. Backed by Genoria AI, each platform ships with AI-powered image analysis (FluoXpert Vision on PMIF-20RS), natural-language workflow orchestration on Path-P96 WF, machine-vision monitoring on PrepALL, and intelligent library-pooling strategies on AIO.

About MGI

Founded in 2016, MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI, stock code:688114.SH) is committed to building core tools and technologies that drive innovation in life science. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as the only provider of a full-stack product portfolio that spans three core segments: SEQ ALL (short- and long-read sequencing), GLI (Generative Lab Intelligence), and Multi-Omics.

To learn more, please visit MGI Tech, LinkedIn, X, Instagram, and YouTube.

About Fraunhofer IIS

As the largest Fraunhofer Institute, Fraunhofer Institute for Integrated Circuits IIS, headquartered in Erlangen, is a global leader in applied research, driving innovation for transformative products and services that shape the digital future.

Across seven research divisions, the institute develops pioneering solutions that advance technological progress, enhance economic competitiveness, and promote a sustainable society. Its strong performance is built on four core areas of expertise: artificial intelligence, microelectronics, data acquisition and analysis, and signal processing and data transmission. These competencies are combined strategically to meet the specific needs of its clients.

About Genoria AI

Genoria AI, a subsidiary of MGI Tech, is an AI4S company building self-evolving labs to scale agentic discovery. Learn more at genoria.ai/en

*for research use only

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302878642
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): TARGET claims the Fraunhofer IIS partnership is to 'validate VisiOmics data in MIKAIA workflows', but SOURCE only states they will 'demonstrate the compatibility' and 'show how researchers can use VisiOmics image data within MIKAIA workflows'. The word 'validate' introduces a material claim not explicitly supported by the SOURCE.
Source Name
Unknown Company
Original Summary

<p>From Tissue to Answer: Integrated Solutions for Tissue and Molecular Pathology, from multiplex immunofluorescence to sample-to-result sequencing, powered by AI STOCKHOLM, Sept. 15, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies...</p>

Image URL
https://global-mgitech.com/wp-content/uploads/2026/08/MGI-1200x630-1.png
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "MGI Tech Launches VisiOmics Pathology System in Europe at ECP 2026", "body_html": "<p><strong>Stockholm -- [CURRENT_DATE] --</strong> MGI Tech Co., Ltd. has made its VisiOmics multiplex immunofluorescence staining and imaging system commercially available across Europe, unveiling the launch at the 38th European Congress of Pathology (ECP 2026) in Stockholm.</p><h5>VisiOmics delivers more than 20-plex protein detection per run, expandable past 100 markers</h5><p>The fully automated system enables researchers to characterize cell populations and their spatial organization within a single tissue section. Cyclic staining extends detection capacity from a baseline of 20-plex to more than 100 protein markers, while walk-away automation covers the entire staining-to-imaging workflow. AI-powered analysis via FluoXpert Vision handles cell segmentation, phenotyping and spatial analysis, supported by a dedicated AI assistant for downstream data visualization.</p><h5>MGI partners with Fraunhofer IIS to validate VisiOmics data in MIKAIA workflows</h5><p>MGI is working with the Fraunhofer Institute for Integrated Circuits IIS to demonstrate compatibility between VisiOmics-generated multiplex immunofluorescence images and MIKAIA, Fraunhofer IIS's digital pathology and spatial biology software. The collaboration targets flexible downstream analysis, letting laboratories combine automated tissue imaging with cell segmentation and phenotyping tools suited to specific research questions.</p><h5>Path-P96 WF processes up to 32 slides per batch for high-throughput tissue imaging</h5><p>MGI also showcased Path-P96 WF, a customisable platform supporting continuous loading and walk-away operation for automated multiplex immunofluorescence staining using standard pathology slides. The system detects more than 100 protein markers through cyclic staining and can be configured for drug discovery applications, including target validation and spatial phenotyping.</p><h5>AIO compresses library prep, sequencing and reporting into an 11-hour sample-to-result workflow</h5><p>The AIO platform requires roughly 10 minutes of hands-on time to move from nucleic acid input to a completed report, and is now open for OEM partnerships in Europe. Alongside it, PrepLPS -- a compact liquid-handling platform with eight independent channels ranging from 0.5 to 1,200 microliters -- has entered Early Access for European laboratories, offering AI-based machine vision for NGS library preparation.</p><p>MGI positions the combined portfolio -- VisiOmics, PrepALL, AIO and Path-P96 WF -- as a full 'From Tissue to Answer' pipeline spanning tissue and molecular pathology, with AI embedded at each processing step through its Genoria AI subsidiary.</p>", "meta_description": "MGI Tech launches VisiOmics multiplex imaging system in Europe at ECP 2026, pairing AI-driven pathology tools with Fraunhofer IIS partnership for tissue analysis.", "seo_keywords": "MGI Tech, VisiOmics, ECP 2026, multiplex immunofluorescence, digital pathology, Fraunhofer IIS, spatial biology, AI pathology", "companies": ["MGI Tech", "Fraunhofer Institute for Integrated Circuits IIS", "Genoria AI"], "industries": ["Laboratory Equipment"], "markets_regions": ["Europe"], "news_type": ["product_launch"], "products": ["VisiOmics"], "themes": ["digital_transformation", "life_sciences_innovation"], "events": ["European Congress of Pathology 2026"], "cta_text": "Learn more about MGI's AI-enabled pathology and multi-omics platforms", "learn_more": "https://genoria.ai/en", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
793680b419b39444a26376d454b0cc59
Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
Original HTML

Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

- DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome1

- Completion of randomization marks another important milestone for the global Phase III DEEp program, with randomization now complete in both pivotal trials

- Dravet syndrome is a rare severe childhood-onset epilepsy and is classified as a developmental and epileptic encephalopathy (DEE)2

VALBY, Denmark, 15 September, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that the last patient has been randomized in DEEp SEA (NCT06660394), a global Phase III clinical trial evaluating the efficacy, safety and tolerability of bexicaserin for the treatment of seizures in children and adults living with Dravet syndrome.

"Completing randomization in DEEp SEA is an important milestone in our work to evaluate bexicaserin in people living with Dravet syndrome. This marks another step forward for the broader Phase III DEEp program and supports our ongoing efforts to advance research for people living with these severe epilepsies," said Tarek Samad, Executive Vice President and Head of Research & Development at Lundbeck. "This milestone reflects the extraordinary commitment of patients and their families, investigators, study teams and advocacy communities around the world. We are deeply grateful for their continued contribution as the study progresses."

DEEp SEA is focused specifically on Dravet syndrome, a rare and severe childhood-onset epilepsy classified as a developmental and epileptic encephalopathy (DEE). Dravet syndrome is associated with treatment-resistant seizures3, highlighting the continued challenge of seizure control for people living with the condition and the need for continued research in this area. DEEs encompass a diverse group of severe epilepsies that typically begin in childhood and are characterized by refractory seizures and developmental stagnation or regression.2

The trial is evaluating the efficacy of bexicaserin, assessed through the reduction in countable motor seizure frequency in children and adults with Dravet syndrome, and is designed as a randomized, double-blind, placebo-controlled multicenter trial. The DEEp SEA trial enrolled over 100 participants aged two to 65 years, and eligible participants may transition into the 52-week DEEp open-label extension (OLE).1 DEEp SEA is one of two pivotal trials in the global Phase III DEEp program. The second, DEEp OCEAN (NCT06719141), is evaluating bexicaserin in children and adults with DEEs, including Lennox-Gastaut syndrome, but excluding Dravet syndrome,4 and completed randomization in July 2026.

Bexicaserin is an investigational compound that is not approved for marketing by any regulatory authority worldwide, and the efficacy and safety of bexicaserin have not been established.

About DEEs

Developmental and Epileptic Encephalopathies (DEEs) are a group of rare neurodevelopmental disorders that typically manifest in early childhood.2 These heterogeneous and severe epilepsy syndromes are characterized by refractory seizures and developmental stagnation or regression. According to the International League Against Epilepsy (ILAE), DEEs currently encompass more than 10 syndromes, including Early Infantile DEE (EIDEE), Infantile Epileptic Spasms Syndrome (IESS), Dravet Syndrome, and Lennox-Gastaut Syndrome (LGS) as well as etiology-specific syndromes such as CDKL5-DEE and KCNQ2-DEE. The etiology is unknown in approximately 50% of cases of DEE.

About bexicaserin

Bexicaserin is an investigational, oral, highly selective superagonist of the 5-HT2C receptor subtype.5 Through its unique and selective binding to 5-HT2C, the potential for adverse effects linked with other receptor subtypes may be minimized. Bexicaserin acts via a dual mode of action, both increasing inhibitory and decreasing excitatory neuron function, consistent with the reduction in seizures associated with DEEs arising from various etiologies.5

Bexicaserin is being evaluated for the treatment of seizures in participants with any type of DEE in a global Phase III clinical program (the DEEp program). The FDA has granted Breakthrough Therapy designation to bexicaserin for the treatment of seizures associated with DEEs for patients two years of age and older. Bexicaserin has also recently been granted Breakthrough Therapy designation in China for the treatment of seizures associated with DEEs.

Bexicaserin is an investigational compound that is not approved for marketing by any regulatory authority worldwide, and the efficacy and safety of bexicaserin have not been established.

About DEEp SEA trial

DEEp SEA (NCT06660394) is a Phase III interventional, randomized, double-blind, parallel-group, placebo-controlled trial evaluating bexicaserin in children and adults with Dravet syndrome.1

The trial comprises a screening period of up to 35 days, followed by a 15-week treatment period consisting of a 3-week titration phase and a 12-week maintenance phase. Participants are randomized to receive either bexicaserin or placebo three times daily, with weight-based dosing used for pediatric participants. Following treatment, participants complete a taper period and safety follow-up or may transition into the 52-week DEEp OLE. The aim of the trial is to evaluate the efficacy, safety, and tolerability of bexicaserin in reducing countable motor seizure frequency in patients with Dravet syndrome.

About DEEp OCEAN trial

DEEp OCEAN (NCT06719141) is a Phase III interventional, randomized, double-blind, parallel-group, placebo-controlled trial evaluating bexicaserin in children and adults with DEEs, including LGS.4

The trial comprises a screening period of up to 35 days, followed by a 15-week treatment period consisting of a 3-week titration phase and a 12-week maintenance phase. Participants are randomized to receive either bexicaserin or placebo three times daily, with weight-based dosing used for pediatric participants. Following treatment, participants complete a taper period and safety follow-up, or may transition into the 52-week DEEp open-label extension study (OLE). The aim of the trial is to evaluate the efficacy, safety, and tolerability of bexicaserin in reducing countable motor seizure frequency in patients with DEEs, including LGS.

Contacts

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

References

- https://clinicaltrials.gov/study/NCT06660394

- Scheffer IE, et al. Epilepsia. 2025;66(4):1014-1023

- Samanta D. Neuropediatrics. 2020;51(2):135-145

- https://clinicaltrials.gov/study/NCT06719141

- Ren A, et al. J Med Chem. 2025;68(11):10599-10618

CONTACT: 

H. Lundbeck A/S

Ottiliavej 9, 2500 Valby, Denmark

+45 3630 1311

[email protected] 

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302878664
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): TARGET states the 15-week treatment period follows a 3-week titration period, but SOURCE says the 15-week treatment period consists of the 3-week titration phase plus the 12-week maintenance phase.
Source Name
Unknown Company
Original Summary

<p>DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome1 Completion of randomization marks another important milestone for the global Phase III DEEp program, with...</p>

Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Lundbeck Completes Randomization in Phase III Dravet Syndrome Trial", "body_html": "<p><strong>Valby, Denmark -- [CURRENT_DATE] --</strong> H. Lundbeck A/S has randomized the last patient in DEEp SEA, a global Phase III trial evaluating its investigational drug bexicaserin in children and adults with Dravet syndrome, completing enrollment in both pivotal studies of the company's Phase III DEEp program.</p><h5>Both pivotal Phase III trials in the DEEp program have now finished randomization</h5><p>DEEp SEA (NCT06660394) enrolled more than 100 participants aged two to 65 years across global trial sites. The randomized, double-blind, placebo-controlled trial is measuring reduction in countable motor seizure frequency over a 15-week treatment period, following a screening phase of up to 35 days and a three-week titration period. Eligible participants can transition into a 52-week open-label extension study.</p><p>The second pivotal trial, DEEp OCEAN (NCT06719141), evaluates bexicaserin in children and adults with developmental and epileptic encephalopathies (DEEs) including Lennox-Gastaut syndrome, but excludes Dravet syndrome. Randomization in that trial completed in July 2026.</p><h5>Dravet syndrome patients face treatment-resistant seizures despite existing therapies</h5><p>Dravet syndrome is a rare, severe childhood-onset epilepsy classified as a DEE, a group of disorders the International League Against Epilepsy says now encompasses more than 10 syndromes, including Early Infantile DEE, Infantile Epileptic Spasms Syndrome, and CDKL5-DEE. Roughly 50% of DEE cases have an unknown etiology. Dravet syndrome patients typically experience treatment-resistant seizures, underscoring continued demand for new therapeutic options.</p><h5>Bexicaserin holds Breakthrough Therapy status in the US and China</h5><p>Bexicaserin is an oral, selective 5-HT2C receptor superagonist designed to both increase inhibitory and decrease excitatory neuron function, a dual mechanism intended to reduce seizures across DEEs with varying etiologies. The US FDA has granted the compound Breakthrough Therapy designation for seizures associated with DEEs in patients aged two and older, and Chinese regulators have granted a similar designation. Bexicaserin remains unapproved by any regulatory authority worldwide, and its efficacy and safety have not yet been established.</p><p>Tarek Samad, Executive Vice President and Head of Research & Development at Lundbeck, said completing randomization in DEEp SEA marks an important milestone for the broader Phase III program and credited patients, families, investigators and advocacy groups for their contribution to the trial's progress.</p>", "meta_description": "Lundbeck completes randomization in Phase III DEEp SEA trial of bexicaserin for Dravet syndrome, finishing enrollment across both pivotal DEEp program studies.", "seo_keywords": "Lundbeck, bexicaserin, Dravet syndrome, Phase III trial, DEEp SEA, epilepsy, developmental epileptic encephalopathy, Breakthrough Therapy", "companies": ["H. Lundbeck A/S"], "industries": ["Biopharmaceuticals"], "markets_regions": ["Europe", "Global"], "news_type": ["clinical_trial_update", "general_news"], "products": ["bexicaserin"], "themes": ["regulatory_compliance", "drug_development"], "events": [], "cta_text": "Details on the DEEp SEA and DEEp OCEAN trial designs are available via ClinicalTrials.gov registrations NCT06660394 and NCT06719141.", "learn_more": "https://clinicaltrials.gov/study/NCT06660394", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
9393243b604bb4ce368513674c017aef
DataX Connect: New Survey Finds Growing Pay and Gender Disparity as Talent Priorities Shift within the Data Centre Sector
Original HTML

DataX Connect: New Survey Finds Growing Pay and Gender Disparity as Talent Priorities Shift within the Data Centre Sector

- The new 2026 Data Centre Salary Survey by DataX Connect reveals nearly 40% of data centre professionals in Europe and the US plan to change jobs within a year

- 41.7% of European respondents worked in energy or in semiconductor and pharmaceutical roles before entering data centres, and in the US, 36.9% came from energy or military backgrounds.

- 46.4% of women surveyed in Europe said their gender had affected their compensation or career progression negatively, compared with 1.7% of men

SOUTHAMPTON, England, Sept. 15, 2026 /PRNewswire/ -- DataX Connect, the world's leading, global data centre recruitment specialist, has today released the results of its 2026 Data Centre Salary Survey, drawing on insights from 1,700+ data centre professionals across the UK, Europe and the United States.

The findings reveal a highly mobile talent market, where competitive pay remains one of the most important considerations, but career development, benefits and progression are increasingly shaping people's decisions to stay or move.

The research also identifies a growing disparity between genders, with more than 46% of women surveyed in Europe stating their gender had affected their compensation or career progression negatively. Almost four in ten professionals in permanent roles in both Europe and the US plan to change companies in the next 12 months, despite 65% of European and 71% of US respondents receiving a salary increase over the past year. In Europe, career development is now the single biggest reason for moving; in the US, salary still leads, with career development close behind. Pay is opening doors, but it is no longer keeping them shut.

Key findings include:

- Pay rises don't guarantee retention: 38.8% of permanent professionals in Europe and 37.8% in the US plan to change companies in the next 12 months. In Europe, career development is the biggest reason for considering a move, cited by 36.0%, while in the US salary leads at 31.4%, closely followed by career development at 29.5%.

- Nearly half of women say their gender has affected their pay or career progression, and for 97% of them, the impact was negative. The issue is even more pronounced regionally, with 46.4% of women in Europe and 51.4% in the US saying gender has affected their compensation or career progression, compared with just 1.7% and 2.2% of men respectively.

- New talent could be closer than we think: 41.7% of European respondents worked in energy or semiconductor/pharmaceutical roles before entering data centres. In the US, 36.9% came from energy or military backgrounds. For employers struggling to find experienced people, adjacent industries offer an important pool of transferable skills.

- The right benefits depend on where you're hiring: In Europe, shares, stocks or equity are the most requested additional benefit, selected by 30.3% of respondents. In the US, car or fuel allowance tops the list at 38.1%, showing why a one-size-fits-all approach to compensation may miss what people actually value in different markets.

Looking ahead

The findings of the DataX Connect 2026 Salary Survey show an industry with significant opportunities for both employers and professionals, but also a talent market that is becoming more nuanced with more requests for competitive benefits such as shares, and clear career progression.

Salaries, for example, still matter, but businesses that understand what people value, why those values are important to them, and those that create clearer routes for progression and look beyond traditional data centre backgrounds will be better placed to find and retain the skills they need.

"The biggest takeaway from this year's Salary Survey is that there isn't one simple answer to the talent challenge. Pay is important, but so is career progression, the benefits people value and, increasingly, where the skills we need actually exist," said Andy Davis, Director, DataX Connect and Data eXec, and host of the Inside Data Centre Podcast. "The challenge now is turning that insight into better decisions around where we recruit, how we attract people and how we retain them. Nearly half of women in our survey say their gender has affected their pay or career progression, and one of the clearest drivers is the lack of visible female role models in senior data centre roles. If people can't see a path for themselves, they're far less likely to stick around and carve one out. Closing that gap, and the gender pay gap alongside it, is vital to the future of this industry."

The full 2026 Data Centre Salary Survey reports for Europe and the United States are available for download from the DataX Connect website.

About DataX Connect

DataX Connect is a specialist recruitment consultancy focused exclusively on the data centre sector. With deep networks across Europe and the United States, DataX Connect places permanent and contract professionals across the full range of data centre roles across construction and operations.

SOURCE DataX Connect

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302878707
Press Eligible
Yes
Press Eligible Reason
Industry salary survey about talent retention, compensation, and workforce trends in the data centre sector.
Source Name
DataX Connect
Original Summary

<p>The new 2026 Data Centre Salary Survey by DataX Connect reveals nearly 40% of data centre professionals in Europe and the US plan to change jobs within a year 41.7% of European respondents worked in energy or in semiconductor and pharmaceutical roles before entering data centres, and in...</p>

Image URL
/wp-content/uploads/2021/09/data-x-fi.png
Content Hash (SHA-256, erste 32 hex)
df6a29049cd5e7b75996350e8a7f0eb6